Although matured DC are capable of inducing effective primary and secondary immune responses in vivo, it is difficult to control the maturation and antigen loading in vitro. In this study, we show that ER-enriched microsomal membranes (microsomes) isolated from DC contain more peptide-receptive MHC I and II molecules than, and a similar level of costimulatory molecules to, their parental DC. After loading with defined antigenic peptides, the microsomes deliver antigenic peptide-MHC complexes (pMHC) to both CD4 and CD8 T cells effectively in vivo. The peptide-loaded microsomes accumulate in peripheral lymphoid organs and induce stronger immune responses than peptide-pulsed DC. The microsomal vaccines protect against acute viral infection. Our data demonstrate that peptide-MHC complexes armed microsomes from DC can be an important alternative to DC-based vaccines for protection from viral infection. 
Introduction
Professional APC can induce powerful T-cell immune responses by capturing antigens, processing them into peptide-MHC complexes (pMHC) and presenting them to T cells [1] . Together with pMHC, APC also provide cosimulatory signals to T cells, which control the magnitude, quality and memory of the induced immune responses [2] . The understanding of the function of APC led to exploration of novel vaccines with the use of antigenarmed APC against infectious diseases and cancer. In both these cases, T-cell-mediated immunity is essential for eradicating virally infected or malignantly transformed cells, particularly against many of the known infectious agents such as tuberculosis, malaria, herpes simplex, papilloma, HIV, Epstein-Barr and hepatitis C viruses [3] . DC, the most potent APC, have been used to elicit protective T-cell immune response to viral infections and cancer in mice and humans with defined antigens [4] . Although some initial promising results were reported, clinical applications have been limited due to difficulties in the quality control of DC matured in vitro, leading to immunogenic heterogeneity of matured DC in induction versus suppression of T-cell responses. The suppressive function of DC subsets largely results in the induction of T cells producing soluble negative regulators such as IL-10, TGF-b and IDO [5] [6] [7] . To overcome the difficulties of DC therapy, cell-free antigen-presenting systems have been reported, including membrane vesicles derived from APC such as exosomes, which are secreted from endosomal compartments of APC and microvesicles derived from plasma membranes of APC after sonication [8, 9] . Exosomes and microvesicles contain MHC I and II and costimulatory molecules and could induce T-cell responses in vivo when mixed with or pre-loaded with defined peptides [9, 10] . However, because it is not known how the pMHCs are processed in these membrane vesicles, both the quality and the quantity of pMHC are difficult to control in the preparation. The MHC molecules on the surface of APC are pre-processed; therefore, the added peptide must compete with endogenous peptides, which may be difficult especially when these are of medium or low affinity [1] .
We have now developed a new form of APC-based but cellfree vaccine by using the ER-enriched microsomes derived from mature DC or other APC. The microsomal membranes contained more peptide-receptive MHC molecules than their parental DC. The level of pMHC can be monitored and controlled quantitatively and qualitatively with reporter peptides. These pMHC I and II armed microsomes possess a high level of costimulatory molecules and can stimulate antigen-specific T cells. When these microsome vaccines were injected i.v. into mice they effectively distributed to peripheral lymphoid organs, induced potent CD4 and CD8 responses and protected from acute viral infection. Thus, the ER-derived microsomes isolated from APC or antigencarrying cells appear to be an effective alternative to DC for both protective and therapeutic applications.
Results
Abundant peptide-receptive MHC I and II and costimulatory molecules in processed microsomes Both MHC I and II molecules are synthesized and matured in the ER. MHC I assemble with antigenic peptides in the ER, while MHC II molecules in the ER are protected from peptide loading by the invariant chain (Ii) until they reach the endocytotic compartments, where the Ii is degraded and exchanged with antigenic peptides under acidic conditions [11] . Therefore, on the surface of APC, most of the MHC I or II molecules are preprocessed with high-affinity peptides as pMHC. In the previous study, we have shown that ER-enriched microsomes contain abundant peptide-receptive MHC I molecules [12] . The microsomes isolated were enriched ER membranes as indicated by the attachment of ribosomes on the cytoplasmic side of the microsomal vesicles and the presence of the ER-resident protein, tapasin ( Fig. 1A and B ) with limited contamination of endosomes as shown by an endosomal marker LAMP2 (Fig. 1B) . To explore whether the peptide-receptive MHC molecules in ER-enriched microsomes from APC can present antigens to T cells, we first examined the ability of MHC molecules in isolated microsomal membranes to assemble with corresponding peptides after an inside-out process consisting of repeated freeze-thawing. Three cycles of freeze-thawing could effectively open the microsomal vesicles, which became pleomorphic (Fig. 1C) . The levels of MHC I and II molecules were similar on the microsomes and cell surface of APC (Fig. 1B and D , data for H2-Ia and -Kb). The H2-Kb molecules in the processed microsomes from the IFN-g-treated DC lines, Jaws II and DC2.4, the macrophage line RAW 309 Cr.1 and the bone-marrow-derived DC could be loaded with the Kbspecific peptide SIINFEKL derived from chicken OVA residues 257-264 as shown by staining with the SIINFEKL-Kb-specific antibody 25-D1. 16 (Fig. 1D , panel SIINFEKL Kb) and by crosslinking Kb with crosslinker-modified SIYNFEKL peptides (Fig. 1E) , consistent with our previous reports [12] . However, only limited amount of MHC I molecules on the surface of APC were peptide receptive (Fig. 1D , panel SIINFEKL Kb and E). To further confirm the retention of peptide-receptive MHC I in the ER, we compared the amount of SIINFEKL-Kb complexes in the microsomes from OVA expressing mouse lymphoma (RMA) cells and the microsomes from RMA cells, which were loaded with exogenous SIINFEKL peptides in vitro. The levels of SIINFEKL-Kb complexes in the microsomes loaded with SIINFEKL were much higher than those in the microsomes from OVA expressing RMA cells (Supporting Information Fig. 1 ), indicating that Kb molecules assembled with endogenous peptides are rapidly transported to cell surface.
To explore the possibility of loading peptides onto microsomal MHC II molecules, a biotin-labeled, H2-Ia restricted peptide ISQAVHAAHAEINEAGR OVA 324-340 was used to detect pMHC II assembly in inside-out converted microsomes. Despite an efficient loading of MHC I molecules, the OVA 324-340 peptide could not be effectively loaded onto MHC II molecules in the inside-out converted microsomes at pH 7.0 ( Fig. 2A) , possibly due to the association of Ii with MHC II. We therefore processed peptide loading in an acidic buffer of pH 5, which dramatically increased the peptide receptiveness of MHC II molecules ( Fig. 2A) . In addition to generating peptide-receptive MHC II molecules, the acidic stripping process also led to the significant increase in peptide-receptive MHC I molecules (Fig. 2B) , which may be due to the dissociation of pre-processed peptides on MHC I molecules. Moreover, acidic treatment released ribosomes from microsomes (Supporting Information Fig. 2 ), which may prevent the induction of antibodies against ribosomes. To compare the level of peptide-receptive MHC II molecules on the cell surface and in the microsomes of APC, the pMHC II on cells and in microsomes were analyzed after loading with a biotin-labeled OVA 324-340 peptide. Results showed that under acidic conditions the microsomes expressed much more of peptide-receptive MHC II molecules than the cell surface (Fig. 1D , panel Bio-OVA324-340). Thus, the developed protocol for the preparation of microsomes with inside-out orientation of peptide-receptive MHC I and II molecules allows effective assembly with antigenic peptides in vitro. Using crosslinker-modified MHC I and biotinlyted MHC II reporter peptides, it was possible to control the level of pMHC in the microsomes, which is essential in controlling the level of T-cell responses.
In addition, analysis of the costimulatory molecules CD54, CD80 and CD86 molecules showed that IFN-g-treated DC2.4 cells expressed well-matched levels on the microsomes and on cells (Fig. 2C) , suggesting that the ER-enriched microsomes can present both pMHC and costimulatory signals to T cells.
Peptide-loaded microsomes induce T-cell responses in vitro
Based on the total protein content, on average 10 4 APC could produce 1-3 mg of microsomes. After the removal of excess .1 cells or 20 mg of microsomal membranes were incubated with 100 mM crosslinker modified and 125I labeled SIYNFEKL peptides and exposed to UV irradiation before lysis. The total lysates were submitted for precipitation with the Y3 antibody specific for Kb molecules and the precipitates were separated on a SDS-gel. The crosslinked Kb molecules were visualized after exposure to X-ray film. The presented data are representative of three experiments. to measuring IL-2 production or for 3 days before proliferation assay. Our results showed that SIINFEKL-loaded microsomes were more potent at inducing T-cell responses in vitro in a peptide-dose-dependent manner than peptidepulsed DC (Fig. 3 , upper panel). Similarly, OVA324-340 peptide-loaded microsomes stimulated IL-2 production in OTII cells more effectively than peptide-pulsed DC (Fig. 3 , lower panel). The immunogenicity of peptide-loaded microsomes could be maintained for more than 6 months if the microsomes were stored in À801C (data not shown). Together, these results present the possible use of a reconstituted cell-free antigen-presenting system as an effective alternative to DC in stimulating both CD4 and CD8 T-cell responses.
Peptide-loaded microsomes are predominately distributed to peripheral lymphoid organs Effective T-cell-based vaccines have to deliver antigens at a sufficient dose to peripheral lymphoid organs for optimal stimulation of effector T cells. It has been reported that antigen-armed DC are better distributed to peripheral LN, if administrated subcutaneously [13] . However, microsomes cannot actively migrate to lymphoid organs; we therefore examined the tissue distribution of peptide-loaded microsomes from CFSE or 35 S-methonine-labeled bone-marrow-derived DC and their parental DC after intravenous administration. Twentyfour hours after injection, 7.4% bone-marrow-derived microsomes had accumulated in the spleen, and 0.66% in the LN. Importantly, after 7 days, 5.64 and 0.81% of bone-marrowderived microsomes were still in the spleen and LN, respectively ( Fig. 4A ), indicating that microsomes accumulate and are retained in major peripheral lymphoid organs. In contrast, only 2.78 and 0.21% of peptide-pulsed and bone-marrow-derived DC were distributed to the spleen and LN 24 h after i.v. injection and this reduced to 0.93 and 0.18% after 7 days (Fig. 4A) . Seven days after injection, microsomes in the spleen accumulated in the periarteriolar lymphoid sheath (PALS), which mainly consists of T cells (Fig. 4B ). DC were also distributed to the PALS 2 days after injection (Supporting Information Fig. 3 ). However, 7 days after injection, very few DC were remained in the peripheral lymphoid tissues and distributed randomly in the follicles, suggesting that they are the dying DC taken up by phagocytes in the follicles (Supporting Information Fig. 3 ). The microsomes accumulated in T-cell areas as indicated by co-staining with anti-T-and B-cell markers (Fig. 4B) . To investigate the possibility that microsomes are endocytozed by APC, the microsomes from CFSE-labeled DC2.4 cells were used for internalization assay with bone-marrow-derived DC. Results showed that FITC-labeled dextran were effectively endocytozed by DC, while endocytosis of microsomes was not detected (Fig. 4C ). Although we cannot exclude the possibility that some of the microsomes were endocytozed by APC in peripheral lymphoid tissues in vivo, the potent T-cell responses suggest that such an accumulation is essential to deliver sufficient quantity of antigens to T cells in lymphoid system.
Microsome vaccine protects against vaccinia virus infection in vivo by induction of both CD4 and CD8 T-cell responses
The capacity of peptide-loaded microsomes in the induction of effective anti-viral immune responses in vivo was evaluated by an in vivo vaccinia viral infection model in C57BL/6 mice. The recombinant vaccinia virus used carries a gene encoding chicken OVA [14] . Five groups of C57BL/6 mice were immunized intravenously with; a mixture of SIINFEKL and OVA 324-340 peptide-loaded microsomes from bone-marrow-derived DC from C57BL/6 at a dose of 20 mg microsomes/mouse or same microsomes but loaded with irrelevant influenza matrix protein (MP) peptides at the same dose or a mixture of SIINFEKL (100 mg) and OVA324-340 (100 mg) or 10 6 DC pulsed with T-cell responses and 4 days after, another 5 were sacrificed for viral clearance study, while the remaining mice were used for clinical study. About 4.3% of CD8 T cells in mice immunized with SIINFEKL and OVA324-340 peptide-loaded microsomes were SIINFEKL specific, while only 1.8% were in mice immunized with peptidepulsed DC (Fig. 5A) . SIINFEKL-specific CD8 T cells were not detected in the other three groups as indicated by tetramer staining (Fig. 5A ). In conjunction with the induction of CD8-specific T cells, the in vitro restimulation of CD4 T cells showed that OVA324-340 peptide-loaded microsomes induced stronger IL-2 production and proliferative responses of CD4 T cells from the mice immunized with a mixture of SIINFEKL and OVA324-340 peptide-loaded microsomes than the mice with peptide-pulsed DC (Fig. 5B and C) . These results indicate that an integrated immune response of both CD4 and CD8 T cells were induced in mice by peptide-loaded microsomes and suggests that the microsomes are more immunogenic than their parental DC.
The clinical symptoms were closely related to the induction of immune responses in vivo. In the infectious dose groups, although a degree of protection was observed in mice immunized with peptide-pulsed DC, only SIINFEKL and OVA324-340 loaded microsomes completely protected against viral infection as these mice had shown no body weight loss and no viral particles detected in lung tissue unlike the other groups ( Fig. 6A and C) . With a sublethal dose of virus, although mice immunized with SIINFEKL and OVA324-340 loaded microsomes showed body weight loss, they were protected from death and recovered rapidly after infection (Fig. 6B) , while two out of ten mice immunized with peptide-pulsed DC died after 5 days (Fig. 6B) . All mice in other groups died ( Fig. 6B) . Furthermore, the spleens were double the size in the protected mice immunized by OVA peptide-loaded microsomes indicating potent immune responses (data not shown) concordant with the observed accumulation of microsomes in peripheral lymphoid organs. These results demonstrate that peptide-loaded microsomes are highly immunogenic and better than live DC to serve as effective vaccines to protect against acute viral infection.
Discussion
Vaccines based on matured DC armed with defined antigens appear very promising for both prophylactic vaccines and immune therapies [15, 16] . However, the difficulties involved in the control of antigen loading, the preparation of matured DC in vitro and the complexities of DC subsets in the induction versus suppression of T-cell activation in vivo limit DC-based vaccine applications [17] . The present study describes an effective alternative to DC therapy using ER-enriched microsomes isolated from DC. The abundant peptide-receptive MHC and costimulatory molecules and accumulation in the peripheral lymphoid organs contribute to the high efficacy of the microsomal vaccine in vivo. The immunogenicity can be maintained for more than 6 months if the prepared microsomal vaccines are stored in À801C or in liquid nitrogen (data not shown), making the prepared vaccine consistent and cost effective.
The sustained accumulation of antigen-carrying microsomes in the peripheral lymphoid organs explains the high efficacy of induced responses in vivo [18] . A possible explanation for such a high accumulation is that matured live DC may actively migrate in and out of the peripheral lymphoid organs, while microsomes from matured DC have the same homing potential, but could not actively migrate out from lymphoid organs. Recently, it has been shown that DC in the peripheral lymphoid organs are actively exchanged with DC in blood [19] in a dynamic equilibrium, which suggests that the low accumulation of injected DC into the lymphoid organs is largely due to the rapid equilibration with endogenous DC. Significantly, most of the injected microsomes are located in the PALS area, which could effectively present antigens to memory T cells [20] [21] [22] .
One of the important findings is the loading of MHC II in the ER-enriched microsomes. Our results provide evidence suggesting that in acidic condition the Ii in microsomes can dissociate from MHC II molecules and generate a peptide-receptive status allowing assembly with exogenous peptides. Although we were not able to directly compare microsomal MHC II assembly with the assembly of MHC II in the endosomal compartments [22] , the induction of CD4 T-cell responses in vitro and in vivo suggests that acidic processed microsomal membranes are able to deliver MHC II-restricted antigenic peptides to CD4 T cells. The acidic treatment also stripped ribosomes from microsomes as well as pre-processed peptides from MHC I molecules, which increases the loading efficiency of pMHC molecules and reduces potential side effects such as anti-ribosome or anti-nuclear responses.
One of the major problems in human DC-based vaccines is the complexity of DC after in vitro maturation. The heterogenic populations of matured DC include both immunogenic and tolerogenic APC, which produce a mixture of inflammatory cytokines as IL-12 and inhibitory factors such as TGF-b, IDO and IL-10 [5, 23, 24] , which hamper the efficacy of immune responses. The microsomes are free from soluble factors, and their preparation is biologically reproducible and consistent at the level of peptide loading and antigenicity when compared with live DC. In addition, the ER-enriched microsomes do not contain cytosolic or nuclear proteins, which reduces potential side effects. We have not found antimicrosome responses in vitro or in vivo, suggesting that the ER-resident proteins were tolerated.
Both exosomes and plasma-membrane-derived vesicles from APC have been reported to induce potent immune responses in vivo [9, 10, 25, 26] . It is however unknown how peptides are processed to pMHC in these vesicles. Some viruses can bud into MHC II-enriched compartments and be released by exosomes [27] , which could limit applications for using autologous exosomes in anti-viral vaccines. The potential advantage of exosomes is that the pMHC class II may be enriched from antigen pre-fed DC due to the processing of pMHC II in endocytotic compartments. For technical reasons, we could not biochemically compare the pMHC II quality in peptide-loaded microsomes in vitro with that in endosomal compartments in vivo. Nevertheless, the observed high efficiency loading and the induction of CD4 Tcell responses demonstrate the immunogenic efficiency of pMHC II in microsomes. Furthermore an important advantage for a microsome vaccine is the ability to directly present pMHC and costimulatory signals to T cells. We demonstrated that microsomes were not endocytozed by DC in vitro. Although we could not exclude the possibility that some of the microsomes in vivo could be endocytosed by APC and the pMHC are indirectly presented by APC to T cells in lymphoid organs, the observed ability to directly activate antigen-specific T cells could be important in microsome vaccines to chronic viral infections or cancer: conditions where endogenous DC are less active in vivo [28, 29] .
After mixing with peptides, the plasma-membrane-derived vesicles also showed the ability to directly interact with T cells and induce responses in vivo [9] . However, as we have shown, the number of peptide-receptive MHC I molecules on the surface of APC is limited due to the presence of pre-processed pMHC I. Therefore, it may be difficult to deliver antigenic peptides with medium or low affinity, which cannot compete with the preprocessed peptides on MHC molecules. Owing to the nature of the sonication methods used in the preparation, some of the ER membranes may also have been present in these preparations [9] , which as we show have abundant peptide-receptive MHC I molecules. If ER-derived microsomes are used, the inside-out processing is required to load peptides effectively and to expose the luminal side of costimulatory and MHC molecules to T cells (data not shown).
Compared with live DC, cell-free membrane vaccines do not include soluble inhibitory factors, but they also exclude inflammatory cytokines such as IL-12. However, the high efficacy of microsomal vaccines indicates that the inflammatory cytokines produced by mature DC are not essential for the induction of effective immune responses in vivo.
In summary, our results present a novel form of vaccine with pMHC I-and II-loaded microsomal membranes. This form of vaccine is comparatively easy to prepare, stable and the quality of preparations can be checked at any step during the procedure. We demonstrate that the microsomal vaccines are better than their parental DC for the induction of potent immune responses against viral infection in vivo.
Materials and methods

Mice and cell lines
OTI and OTII transgenic mice on the C57BL/6 background expressing a TCR specific to the H2-Kb-SIINFEKL and specific for H2-Ia-OVA324-340 peptide complex, respectively, were kindly provided by Dr. Kioussis D. MRC National Institute for Medical Research, London. C57BL/6 mice were purchased from Harlan UK, (Oxon, England). All animals were maintained in pathogenfree facilities at the Brunel University. Jaws II, macrophage RAW309Cr.1 were obtained from American Type Culture Collection (ATCC). DC2.4 DC line was kindly provided by Dr. Mann D. Southampton, UK. All lines were cultured in RPMI 1640 Figure 5 . Induction of CD4 and CD8 T-cell responses by peptide-loaded microsomes in vivo. CD57BL/6 mice were injected i.v. with a mixture of SIINFEKL and OVA324-340 loaded microsomes (20 mg/mouse) from bone-marrow-derived DC and boosted once after 7 days. The mice injected with irrelevant MP peptide-loaded microsomes, mixture of SIINFEKL and OVA 324-340 peptides and PBS serve as controls. Seven days after boosting, total splenocytes were stained with SIINFEKL tetramer and CD8 (A). For CD4 T-cell responses, CD4 T cells were isolated from splenocytes and stimulated in vitro at 2 Â 10 5 CD4 T cells per well with the corresponding stimuli as indicated. Two days after stimulation, IL-2 production was measured by ELISA (C) and 3 days after proliferation responses were detected by 3 [H] incorporation (CPM) (mean of triplicate cultures7SD) after exposure to 3 [H]thymidine for 8 h (B).
or DMEM supplement with 10% FBS (Invitrogen). For Jaws II cells, the culture also contained GM-CSF (Invitrogen) at 5 ng/mL. For antigen presentation, the Jaws II, DC2.4 and RAW309Cr.1 cells were treated with IFN-g at 100 IU/mL for 24 h.
Bone-marrow-derived DC
Immature DC were generated from bone marrow progenitors by culturing them in the presence of GM-CSF and maturated by LPS stimulation as described previously [11] . At the end of IFN-g or LPS treatment, the dead cells were less than 5% in the cell lines and 15% in bone-marrow-derived DC.
Antibodies and flow cytometry
FITC-conjugated antibodies to CD54, CD80, CD86, 25-D1.16 and FITC-conjugated Streptavidin; PE-conjugated antibodies to H2-Ia and Y3 were from BD Biosciences. Antibodies against tapasin and H2 molecules were described previously [12] . Anti-LAMP2 antibody was from eBioscience. Kb-SIINFEKL Pentamer was from Proimmune. Antibodies used for immunoblotting of mouse CD54 (AF796), CD80 (AF740) and CD86 (AF-441-NA) were from R&D systems. A PE-Pro5TM was used for the analysis of fluorescently labeled cells and the medium fluorescent intensity from three experiments was presented. The isotype Ig was used as background controls for all the staining of both cells and microsomes. The setting of side-scatter and forward-scatter was the same between cells and microsomes. Owing to the uneven sizes of microsomal vesicles, the entire events detected in side-scatter and forward-scatter were used for the analysis on fluorescent channels. The medium fluorescent intensity was then compared. CD4 or CD8 microbeads (Miltenyi Biotec)
were used for isolation of CD4 or CD8 T cells from spleens of OTII or OTI mice, respectively, according to the manufacturer's protocol.
Peptides and peptide modification
Peptides were synthesized by Invitrogen and purified to more than 95% purity. The Àamino group of lysine in the H2-Kbspecific SIYNFEKL peptide was covalently modified by a photoreactive crosslinker and labeled with iodination ( 125 I) as described previously [30] . The N-terminus of peptide OVA324-340 was labeled and purified with a biotin-labeling kit (Pierce).
Preparation of ER-enriched microsomal membranes
Microsomes from cell lines or bone-marrow-derived DC were prepared and purified according to our previous publication [30] . Briefly, cells were washed and resuspended in homogenization buffer. After homogenization, tonicity was restored to 0.15 M NaCl. The nuclear, mitochondria and larger cell debris were removed by centrifugation at 10 000g. The total microsomes were recovered by centrifugation at 100 000g and subfractionated by flotation in sucrose gradients. The microsomes were layered on top of 5 mL of 0.33 M sucrose, layered in turn on top of a discontinuous sucrose gradient consisting of 2 mL of 2 M and 1 mL of 2.5 M sucrose. Centrifugation in a TH-641 rotor for 16 h at 110 000g at 41C yielded a microsome band on top of the 2 M sucrose cushion, which was collected and resuspended in RM buffer (250 mM Sucrose, 50 mM triethanolamine-HCl, 50 mM KOAc, 2 mM MgOAc2, 1 mM DTT). Before preparation, cell lines and bonemarrow-derived DC were activated by treatment of 100 IU/mL of IFN-g or 1 mg/mL of LPS for 24 h, respectively.
35
S-methionine (Amersham) and the CFSE-labeled microsomal membranes were prepared from bone-marrow-derived DC after labeling with either 1mCi 35 S-methoinine for 6 h or 2.5 mM CFSE (Molecular Probe) for 10 min.
Processing and peptide loading of microsomes
The microsomes in RM buffer were first processed by freeze-thaw (30 s in liquid nitrogen and 5 min at 371C) three times, followed by addition of an equal amount of stripping buffer (0.26 M citric acid, 132 mM Na 2 HPO 4 , 2% BSA, pH 3) and incubation for 3 min on ice. The microsomal membranes were recovered by centrifugation through a 0.5 M sucrose cushion on an airfuge and resuspended in RM buffer. For MHC I loading, peptides at 500 mg/mL or as indicated and human b2-microglobin (5 mg/mL) were loaded to the microsomal membranes by incubation for 1 h at 371C. After loading the excess peptides were removed by centrifugation through a 0.5 M sucrose cushion on an airfuge and the loaded microsomes were resuspended as homogenous population in culture medium. For MHC II, after the freeze-thaw process, the microsomes in RM buffer were mixed with equal volume of stripping buffer and peptide at 500 mg/mL or as indicated for 5 min at 371C. After loading excess peptides were removed by centrifugation through a 0.5 M sucrose cushion on an airfuge and the loaded microsomes were resuspended as homogenous population in culture medium.
In vitro stimulation of T cells
The OTI or OTII T cells were isolated from spleens of OTI or OTII transgenics by positive selection using a MACS system (Miltenyi Biotec), with purity consistently above 95% as defined by FACS analysis with anti-CD8 or anti-CD4 antibodies. A total of 1 Â 10 5 T cells were incubated at 371C with 1-4 mg of peptide-loaded microsomes for 48 h. IL-2 production was then measured by ELISA (R&D). For proliferation assay, [ 3 H]thymidine at 1 mCi/mL was added after 3 days of culture and the cells were harvested after 8 h. When APC were used for stimulation, IFN-g-treated APC were pulsed with peptides at 500 mg/mL or as indicated for 1 h at 371C in HBSS containing 5% FBS and for MHC I loading 5 mg/mL human b2-microglobulin was added. After peptide pulsing, APC were washed and irradiated at 4000 Rad. A total of 1 Â 10 5 peptide-loaded APC were cultured in vitro with 1 Â 10 5 OTI or OTII cells.
In vivo distribution of microsomal membranes or DC
Microsomes were purified from either CFSE or 35 S-methoininelabeled bone-marrow-derived DC. An aliquot of 20 mg of peptideloaded microsomes or 1 Â 10 6 peptide-pulsed DC was injected into C57BL/6 mice i.v. At various times as indicated, spleen, lung, LN and liver were collected and CPM was measured. The percentage of accumulated microsomes or DC was calculated as CPM/gram of the organ and divided by the total CPM of injected microsomes or DC. The distribution of CFSE-labeled microsomes was morphologically analyzed on the frozen sections of the spleen 7 days after injection. The frozen sections were also used for staining with PE-labeled anti-B220 antibody (BD Biosciences) or rabbit anti-CD3 antibody (BD Biosciences) followed with Alexa Fluor 594-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Lab).
Internalization assay
Bone-marrow-derived DC were incubated with microsomes isolated from CFSE-labeled DC2.4 cells or with FTIC-labeled dextran for 5 h at 371C. Free-microsomes or dextran were removed by low-speed centrifugation at 2500 rpm in PBS. Cells were then fixed and analyzed by fluorescent microscopy.
Immunization
Microsomes from bone-marrow-derived DC or bone-marrow DC were loaded either with OVA SIINFEKL or OVA OVA324-340 as immunogens, or with an HLA-A2-restricted epitope of the influenza matrix protein (GILGFVFTL) as an irrelevant control peptide. A total of 1 Â 10 6 cells or 20 mg microsomes in 100 mL of physiologic saline were injected into the dorsal tail vein of each mouse after 7 days; the same dose was given again for boosting.
Viral infection
Mice were infected intranasally with the recombinant vaccinia virus encoded with chicken OVA [31] in 50 mL at the indicated doses. The mice were weighed and observed for illness daily, as described previously [31] . In vivo replication of vaccinia virus was examined by plaque assay on lung tissues, which were removed, weighed and ground with a mortar and pestle. Serial 10-fold dilutions of clarified supernatants were used to infect subconfluent monolayers of BSC40 cells in triplicate in 24 well plates. After 1 h, the plates were covered in 0.75% methylcellulose in 10% MEM and incubated at 371C. The cells were fixed with formalin 2 days after infection and stained with 2% crystal violet in 40% methanol, and plaques were counted under a dissecting microscope. Data are presented as geometric mean log 10 PFU per gram of lung at dilutions that produced more than five plaques per well.
Ex vivo analysis of antigen specific T cells
For CD8 T cells, splenocytes were stained with FITC-conjugated anti-CD8 (BD Biosciences). After washing, cells were stained with either PE-conjugated Kb-SIINFEKL Pentamer (Proimmune) or isotype-matched controls, and analyzed by FACS. For evaluation of CD4 T-cell responses, CD4 T cells were purified from spleen and LN by CD4-coated magnetic beads (Miltenyi Biotec) to more than 90% as measured by PE-CD4 antibody on FACS. A total of 10 5 CD4 T cells were cultured with either 2 mg of OVA320-340 peptide-loaded microsomes from bone-marrow-derived DC or 1 Â 10 5 DC pulsed with the same peptide for 48 h before measuring IL-2 production by ELISA (BD Bioscience) or 3 days before proliferation assay with 3 H-TdR (Amersham) incorporation.
Statistics
Statistical comparisons were performed using Student's t-test; survival was plotted using Kaplan-Meier curves and statistical relevance was determined using log-rank comparison. Unless noted, data were presented as means7SD of pooled data from four to six independent experiments.
